Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm

Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm This includes the approval of Merck’s checkpoint inhibitor Keytruda (pembrolizumab), which has been approved in over 25 indications across 16 tumour types. ... Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations,

Keytruda doubles five-year survival rate in NSCLC

Keytruda doubles five-year survival rate in NSCLC At the five-year time point, the overall survival rate for patients receiving Keytruda was twice as high compared to chemotherapy (31.9% and 16.3% respectively). ... Keytruda has become the new standard-of-care treatment for newly diagnosed NSCLC, after

Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer

Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer Merck &Co/MSD’s checkpoint inhibitor Keytruda cut the risk of disease progression or death by 35% in patients with locally advanced or metastatic oesophageal and gastroesophageal junction (GEJ) cancer. ... Keytruda is already approved as a monotherapy

BMS eyes approval for second Opdivo combo in kidney cancer

BMS eyes approval for second Opdivo combo in kidney cancer However, it has been facing competition from Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (axitinib) after the combination treatment won US Food and Drug ... Topline results from the phase 3

Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial

Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial Despite the NSCLC market being largely dominated by Merck &Co/MSD’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....

Infographics